Literature DB >> 19573665

Arteriovenous fistulas for hemodialysis access in children and adolescents using the proximal radial artery inflow site.

William C Jennings1, Martin A Turman, Kevin E Taubman.   

Abstract

INTRODUCTION: Hemodialysis (HD) for children and adolescents with renal failure is increasingly common in the United States. Consensus opinion views an arteriovenous fistula (AVF) as the best long-term access option, although catheter-based HD remains the most common vascular access in children and has greater risks of complications and higher mortality rates than AVF access. This report reviews our experience with children and adolescents undergoing vascular access operations.
METHODS: We reviewed 721 consecutive vascular access patients who had vascular access surgery by a single surgeon during the previous 5 years. Ten patients 20 years or younger were included in this study. In addition to physical examination, each patient had preoperative vascular ultrasound mapping by the operating surgeon. A radiocephalic AVF (RC-AVF) at the wrist was the first choice for dialysis access when feasible; however, the patients in this report were generally seen after years of intravenous access and venipunctures that necessitated more proximal AVF constructions. A proximal radial artery AVF (PRA-AVF) was our most common choice for vascular access when an RC-AVF was not suitable.
RESULTS: Patient ages were 9 to 20 years (mean, 16). Seven were male. Renal failure was caused by glomerulnephitis in 4 patients, 3 had a history of obstuctive uropathy, 2 were diabetic and one had congenital nephrotic syndrome. Eight patients had PRA-AVFs created, 1 had an RC-AVF, and 1 patient required a transposition AVF. Follow-up was 4 to 56 months (mean, 32 months). Primary, primary-assisted, and cumulative patencies were 77.8%, 100%, and 100% at 24 months. No prosthetic grafts were used in any vascular access patient during the study period.
CONCLUSION: We found HD access in children and adolescents was reliably established through use of a PRA-AVF when an RC-AVF was not feasible. Access sites were often possible through the upper arm cephalic veins and/or with retrograde flow into the forearm. Cumulative (secondary) patency was 100% at 24 months.

Entities:  

Mesh:

Year:  2009        PMID: 19573665     DOI: 10.1016/j.jpedsurg.2008.11.001

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  5 in total

1.  Predictors of patency for arteriovenous fistulae and grafts in pediatric hemodialysis patients.

Authors:  Ali Mirza Onder; Joseph T Flynn; Anthony A Billings; Fang Deng; Marissa DeFreitas; Chryso Katsoufis; Matthew M Grinsell; Larry T Patterson; Jennifer Jetton; Sahar Fathallah-Shaykh; Daniel Ranch; Diego Aviles; Lawrence Copelovitch; Eileen Ellis; Vimal Chanda; Ayah Elmaghrabi; Jen-Jar Lin; Lavjay Butani; Maha Haddad; Olivera Marsenic Couloures; Paul Brakeman; Raymond Quigley; H Stella Shin; Rouba Garro; Hui Liu; Javad Rahimikollu; Rupesh Raina; Craig B Langman; Ellen G Wood
Journal:  Pediatr Nephrol       Date:  2018-09-27       Impact factor: 3.714

2.  Good outcomes for arteriovenous fistula with buttonhole cannulation for chronic hemodialysis in children and adolescents.

Authors:  Brittany Garza; Jessica Geer; Sarah J Swartz; Poyyapakkam Srivaths; Tam T T Huynh; Eileen D Brewer
Journal:  Pediatr Nephrol       Date:  2022-05-05       Impact factor: 3.714

3.  Cephalic vein cutdown for totally implantable central venous port in children: a retrospective analysis of prospectively collected data.

Authors:  Kyu-Hwan Jung; Suk-Bae Moon
Journal:  Can J Surg       Date:  2014-02       Impact factor: 2.089

4.  Correlation between CRP and early failure of arteriovenous fistula (AVF).

Authors:  Morteza Khavanin Zadeh; Saman Mohammadipour; Zahra Omrani
Journal:  Med J Islam Repub Iran       Date:  2015-06-08

5.  Two-year cumulative patency of endovascular arteriovenous fistula.

Authors:  Gerald A Beathard; Terry Litchfield; William C Jennings
Journal:  J Vasc Access       Date:  2019-09-28       Impact factor: 2.283

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.